Highlights aTyr Pharma, Inc.

Equities

LIFE

US0021202025

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
1.69 ^USD	-1.74%		+4.97%	+19.86%

05-02	ATyr Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-02	Earnings Flash (LIFE) ATYR PHARMA Reports Q1 Revenue $235,000	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ATyr Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
Earnings Flash (LIFE) ATYR PHARMA Reports Q1 Revenue $235,000	05-02	MT
ATyr Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
ATyr Pharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-14	CI
ATyr Pharma, Inc. Announces Plans to Initiate an Individual Patient Expanded Access Program for Its Lead Therapeutic Candidate, Efzofitimod, for Patients with Pulmonary Sarcoidosis	02-21	CI
ATyr Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Earnings Flash (LIFE) ATYR PHARMA Posts Q3 Revenue $353,000	11-09	MT
Atyr Pharma, Inc. Announces Dosing of First Patient in Phase 2 Efzo-Connect?? Study of Efzofitimod in Patients with Ssc-Ild	31/10/23	CI
Atyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, Fvc and Patient Reported Outcomes	11/09/23	CI
ATyr Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23	CI
ATyr Pharma's Efzofitimod Gets Orphan Drug Label from European Commission for Systemic Sclerosis	22/06/23	MT
ATyr Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	09/05/23	CI
ATyr Pharma, Inc. to Present Data Identifying Fibrosis Target for tRNA Synthetase Candidate Atyr0101 At Keystone Symposia on Fibrosis Pathogenesis and Resolution	21/03/23	CI
ATyr Pharma, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	09/03/23	CI
ATyr Pharma, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	09/03/23	CI
Earnings Flash (LIFE) ATYR PHARMA Reports Q4 Revenue $10.4M	09/03/23	MT
ATyr Pharma, Inc. Announces Phase 2 Study of Efzofitimod in Patients with Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD) Following FDA Clearance of IND Application	01/03/23	CI
ATyr Pharma Secures Patent Allowance for Efzofitimod Combination Treatment in EU	19/01/23	MT
Atyr Pharma Announces LTBP1 as Target of DARS tRNA Synthetase Fragment	15/12/22	CI
ATyr Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/11/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights aTyr Pharma, Inc.

Equities

LIFE

US0021202025

Highlights

Filters